Phosphoproteomic analyses have revealed resistance mechanisms, including EGFR/HMAG1 hyperphosphorylation and SRC-PRKCD cascade activation in EGFR inhibitor-resistant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.